COMMUNIQUÉS West-GlobeNewswire

Telix to Host R&D Day in New York City on September 22, 2026
05/08/2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday [...]
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
05/08/2026
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 [...]
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
05/08/2026
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from [...]
BioCryst Reports Second Quarter 2026 Financial Results
05/08/2026
— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue [...]
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
05/08/2026
Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges [...]
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
05/08/2026
CALGARY, Alberta, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Bluesight Launches Revenue Optimization Capabilities, Expanding Margin Insights for Hospital Pharmacies
05/08/2026
Alexandria, Virginia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CostCheck, a drug procurement optimization tool used by more than 500 hospitals, now factors in top-line revenue alongside cost savings to provide pharmacy teams a [...]
Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease
05/08/2026
Scottish National Investment Bank joins existing investors Roche Venture Fund, Epidarex Capital, Sofinnova Partners and BioGeneration Ventures Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company [...]
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
05/08/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 05, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
Grace Therapeutics Announces $10 Million Private Placement
05/08/2026
Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “ [...]
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
04/08/2026
New system expands the Company’s leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. MENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2026
SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2026
LEXINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
04/08/2026
RESEARCH TRIANGLE PARK, N.C. and BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences [...]
Sienna Reports Second Quarter 2026 Financial Results and Forms Redevelopment Joint Venture with Fiera Infrastructure
04/08/2026
MARKHAM, Ontario, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2026. Highlights [...]
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
04/08/2026
Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic [...]
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
04/08/2026
Dallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock [...]
LeMaitre Q2 2026 Financial Results
04/08/2026
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0. [...]
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
04/08/2026
-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 -- Hosted a Key Opinion [...]

Pages